HomeSubscribeLogin
HomeLogout

ValuentumAd

Official PayPal Seal













Apr 30, 2018
Portfolio Diversification Begins at Alexion; Shares Cheap
Image Source: Alexion. We view the acquisition of differentiated, late-stage molecules at an attractive rate as the optimal use of free cash flow for many in the biotech industry. The finite commercial life of a patented drug forces continued innovation as near-total revenue erosion is a certainty once patent protection has lapsed. Let’s review some of the recent events at Alexion to gain a further understanding of the underlying trends affecting the business.
Apr 27, 2018
Dividend Growth Ideas Microsoft and Intel Deliver Strong Free Cash Flow
Microsoft and Intel continue to deliver robust levels of free cash flow, which are core drivers of their respective dividend strength.
Apr 27, 2018
GM and Ford Tune Up Operations for the Future of Automaking
Image Source: GM's first-quarter earnings report. The US auto behemoths continue to place a greater importance on efficient operations and the health of their bottom lines. The industry may be reaching a relative peak in terms of light vehicle production for this economic cycle, and the future of the auto landscape remains uncertain.
Apr 26, 2018
Best Ideas: Reiterating ~$240 Fair Value on Facebook; Adding Chipotle
We couldn’t be more pleased with Facebook’s first-quarter 2018 results, and we are reiterating our ~$240 per-share fair value estimate on the company. We’re also adding Chipotle as an idea to the simulated Best Ideas Newsletter portfolio, and we’re putting three other speculative considerations on your radar.
Apr 26, 2018
What’s Working (or NOT Working) in Today’s Market?
Image shown: Crude oil continues to lead gainers while consumer staples, REITs, and energy MLPs continue to get shellacked. Let’s take a look at what’s been working and what’s not been working in the market thus far in 2018. To little surprise, in our opinion, commodity prices have been the leaders, while interest-rate sensitive equities have been the laggards. We’ve been expecting this.
Apr 25, 2018
The Transformation of Novartis Continues
Image Source: Taki Steve. Leadership change can often bring a great deal of uncertainty especially when a new leader is replacing a successful CEO. In the case of Novartis, we are witnessing a focused effort to streamline the business: a deliberate attempt to shift focus from a sprawling healthcare enterprise towards a more pure-play pharma/biotech powerhouse with an innovative, cutting-edge product portfolio.
Apr 25, 2018
Demand Bouncing Off Multi-Year Bottom at Caterpillar
Improvement in Caterpillar’s underlying end markets is driving its performance, and management took the opportunity following a solid showing in the first quarter of 2018 to raise its bottom-line guidance for the full year. The market, however, did not look favorably on management’s comments that the first quarter should be expected to be the “high-water mark” for the year in terms of margin performance. We’ve updated our fair value estimate of shares.
Apr 24, 2018
United Tech Ups Guidance; Outlook Bodes Well For Aerospace Supply Chain
Image Source: hj_west. We think activist pressure on United Technologies is unwarranted, and we were highly encouraged by the company’s execution during the first quarter of 2018. Performance at Pratt & Whitney and UTC Aerospace Systems bodes well for the aerospace supply chain.
Apr 23, 2018
Market Not Overreacting to Hasbro’s Miss; Shares Up
Toy giant Hasbro turned in a poor first-quarter report April 23, but the market is not overreacting as the issues weighing on its performance are largely transient, in our view.
Apr 23, 2018
Incyte’s Ongoing Disappointments and Ultragenyx’s Exciting Development
Image shown: Ultragenyx's promising pipeline of opportunities. Ultragenyx March 2018 Presentation. The pharma/biotech sector, unlike other mainline industries, is driven by the clinical data readouts on the next-gen molecules in the clinical pipeline. We have witnessed many exaggerated moves with an often-binary outcome on the smaller single molecule entities, but we also have witnessed a negligible impact on the broader, more-diverse industry behemoths. We wanted to touch on a few recent data readouts to illustrate the volatile, risky yet potentially lucrative nature of the industry.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.